Company News: Page (1) of 1 - 09/29/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Immunovaccine to Present at Upcoming Investor Conferences

(September 29, 2017)

HALIFAX, Nova Scotia, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced  Chief Executive Officer Frederic Ors is scheduled to present an overview of the Company’s recent progress and future strategy at two upcoming investor conferences.

Presentation details for the 2017 BIO Investor Forum include:

Date: Tuesday, October 17Time: 11:30 a.m. PT


Location: The Westin St. Francis in San Francisco, CA
Room: Elizabethan C presentation room

Presentation details for the 2017 Investival Showcase include:
Date: Tuesday, November 14
Time: 2:15 p.m. UTC
Location: The Hilton Waldorf, Aldwych, London
Room: Adelphi 1

To arrange a meeting with management at these conferences, please contact Anna Fryday at [email protected]

The presentations will be available on Immunovaccine’s website at www.imvaccine.com following the meeting.

About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at www.imvaccine.com.

Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contacts for Immunovaccine:

MEDIA 
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: [email protected]

INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: [email protected]

Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: [email protected]


Page: 1


Related Keywords:

[ServletException in:/common/ads/links.jsp] Unable to load class for JSP'

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved